Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NTR-101 in acute alcohol-associated hepatitis
NCT06750588Phase 1Not yet recruiting
- Sponsor
- Nterica Bio, Inc.
- Start
- Nov 2025
- Primary completion
- Apr 2026
- Modality
- Single Strain Products, Multi-strain Products
- Countries
- 1
01
Overview
Phase 1, open-label trial of NTR-101 in alcoholic hepatitis (AH) (4 cohorts), sponsored by Nterica Bio, Inc. Primary endpoints: Frequency of adverse events at Day 35 and Changes in liver function at Day 35. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
NTR-101
03
Conditions
alcoholic hepatitis (AH)
Beyond the preview
Go deeper on NCT06750588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06750588.